Ademi LLP is investigating Entero (Nasdaq: ENTO) for possible breaches of fiduciary duty and other violations of law in its transaction with Journey.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the reverse merger transaction, the shareholders of Journey will acquire 99% of the equity of Entero. The transaction agreement unreasonably limits competing transactions for Entero by imposing a significant penalty if Entero accepts a competing bid. Entero insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Entero’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113298671/en/